Research Article | Volume: 15, Issue: 10, October, 2025
Factor Xa inhibition mitigates tacrolimus-induced tubulointerstitial fibrosis via the PI3K/p-AKT pathway
Next Article
Research Article | Volume: 15, Issue: 10, October, 2025
Tacrolimus (TAC) is one of the effective immunosuppressant drugs frequently used in different organ transplantation to prevent allograft rejection. The use of TAC is associated with nephrotoxicity, especially tubulointerstitial fibrosis (TIF), a complication that limits its use. The coagulation system involvement in the development of TIF-resulted from TAC, is not known. Therefore, the aim of the current work is to explore the role of the coagulation system activation against TAC-induced TIF. Furthermore, the possible protective role of the indirect Factor Xa inhibitors, rivaroxaban (RIV), against TAC-inducing TIF is also investigated. Normal, RIV-treated, TAC-treated, and TAC+RIV-treated groups were used. Renal toxicity markers, blood parameters, histopathology changes, and renal expression of fibrinogen, p-AKT, PI3K, TGF-β, and fibronectin were assessed. RIV-treated mice displayed improvement in renal architecture, blood glucose level, and renal and blood parameters deteriorated by TAC treatment. Moreover, RIV decreased tubular and glomerular expression of fibrinogen, p-AKT, PI3K, TGF-β, and fibronectin, increased by TAC treatment. FX activation mediates TAC-induced TIF through PI3K/p-AKT pathway. Therefore, RIV may serve as an effective adjunctive therapy to mitigate the renal consequences of calcineurin inhibitor use.
Abdel-Bakky MS, Alharbi NB. Factor Xa inhibition mitigates tacrolimus-induced tubulointerstitial fibrosis via the PI3K/p-AKT pathway. J Appl Pharm Sci. 2025;15(10):135-143. https://doi.org/10.7324/JAPS.2025.25203
1. Nady ME, Abd El-Raouf OM, El-Sayed EM. Linagliptin mitigates TGF-β1 mediated epithelial–mesenchymal transition in tacrolimus-induced renal interstitial fibrosis via Smad/ERK/P38 and HIF-1α/LOXL2 signaling pathways. Biol Pharm Bull. 2024;47(5):1008–20. doi: https://doi.org/10.1248/bpb.b23-00737
2. Ume AC, Wenegieme TY, Shelby JN, Paul-Onyia CDB, Waite AMJ, Kamau JK, et al. Tacrolimus induces fibroblast-to-myofibroblast transition via a TGFb-dependent mechanism to contribute to renal fibrosis. Am J Physiol Renal Physiol. 2023;324:F433–45. doi: https://doi.org/10.1152/ajprenal.00226.2022
3. Knops N, Ramazani Y, De Loor H, Goldschmeding R, Nguyen TQ, van den Heuvel LP, et al. Tacrolimus induces a pro-fibrotic response in donor-derived human proximal tubule cells dependent on common variants of the CYP3A5 and ABCB1 genes. Nephrol Dial Transplant. 2023;38(3):599–609. doi: https://doi.org/10.1093/ndt/gfac237
4. Wang D, Chen X, Fu M, Xu H, Li Z. Tacrolimus increases the expression level of the chemokine receptor CXCR2 to promote renal fibrosis progression. Int J Mol Med. 2019;44(6):2181–8. doi: https://doi.org/10.3892/ijmm.2019.4368
5. Oe Y, Takahashi N. Tissue factor, thrombosis, and chronic kidney disease. Biomedicines. 2022;10(11):2737. doi: https://doi.org/10.3390/biomedicines10112737
6. Horinouchi Y, Ikeda Y, Fukushima K, Imanishi M, Hamano H, Izawa-Ishizawa Y, et al. Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis. Sci Rep. 2018;8(1):10858. doi: https://doi.org/10.1038/s41598-018-29008-2
7. Bedreli S, Straub K, Achterfeld A, Willuweit K, Katsounas A, Saner F, et al. The effect of immunosuppression on coagulation after liver transplantation. Liver Transpl. 2019;25(7):1054–65. doi: https://doi.org/10.1002/lt.25476
8. Fang L, Ohashi K, Ogawa H, Otaka N, Kawanishi H, Takikawa T, et al. Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial-mesenchymal transition and inflammatory response. Physiol Rep. 2022;10(5):e15218. doi: https://doi.org/10.14814/phy2.15218
9. Gill R, Meghrajani V. Tacrolimus-induced thrombotic microangiopathy after orthotopic heart transplant: a case report. Cureus. 2022;14(6):e25874. doi: https://doi.org/10.7759/cureus.25874
10. Wagner NM, Dressel T, Schäfer K, Konstantinides S. Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice. Thromb Res. 2012;130(5):793–8. doi: https://doi.org/10.1016/j.thromres.2012.01.002
11. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–61. doi: https://doi.org/10.1096/fj.07-9574LSF
12. Lopes CT, Gallo AP, Palma PVB, Cury PM, Bueno V. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. Transplant Proc. 2008;40(3):856–60. doi: https://doi.org/10.1016/j.transproceed.2008.02.051
13. Cohen J. A power primer. Psychol Bull. 1992;112(1):155–9. doi: https://doi.org/10.1037//0033-2909.112.1.155
14. Suhariningsih S, Glory S, Khaleyla F, Kusumawati HN, Septriana M, Susilo Y, et al. Ameliorative and renoprotective effect of electrical stimulation on blood sugar, blood urea nitrogen (BUN), creatinine levels, and the islets of langerhans weight in diabetic mice. Vet Med Int. 2022;2022:7922892. doi: https://doi.org/10.1155/2022/7922892
15. Abdel-Bakky MS, Hammad MA, Walker LA, and Ashfaq MK. Silencing of tissue factor by antisense deoxyoligonucleotide prevents monocrotaline/LPS renal injury in mice. Arch Toxicol. 2011;85:1245–56. doi: https://doi.org/10.1007/s00204-011-0663-8
16. Abdel-Bakky MS, Aldakhili ASA, Ali HM, Babiker AY, Alhowail AH, Mohammed SAA. Evaluation of cisplatin-induced acute renal failure amelioration using fondaparinux and alteplase. Pharmaceuticals. 2023;16(7):910. doi: https://doi.org/10.3390/ph16070910
17. Binker MG, Binker-Cosen AA, Richards D, Gaisano HY, de Cosen RH, Cosen-Binker LI. Chronic stress sensitizes rats to pancreatitis induced by cerulein: role of TNF-α. World J Gastroenterol. 2010;16(44):5565–81. doi: https://doi.org/10.3748/wjg.v16.i44.5565
18. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508. doi: https://doi.org/10.2215/CJN.04800908
19. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509–15. doi: https://doi.org/10.1111/j.1742-1241.2009.02070.x
20. Ten Cate H. Tissue factor-driven thrombin generation and inflammation in atherosclerosis. Thromb Res. 2012:129 Suppl 2:S38–40. doi: https://doi.org/10.1016/j.thromres.2012.02.028
21. Torramade-Moix S, Palomo M, Vera M, Jerez D, Moreno-Castaño AB, Zafar MU, et al. Apixaban downregulates endothelial inflammatory and prothrombotic phenotype in an in vitro model of endothelial dysfunction in uremia. Cardiovasc Drugs Ther. 2021;35(3):521–32. doi: https://doi.org/10.1007/s10557-020-07010-z
22. Press R, de Fijter J, Guchelaar H-J. Individualizing calcineurin inhibitor therapy in renal transplantation - current limitations and perspectives. Curr Pharm Des. 2010;16(2):176–86. doi: https://doi.org/10.2174/138161210790112782
23. Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37(1):37–61. doi: https://doi.org/10.1210/er.2015-1084
24. Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131–41. doi: https://doi.org/10.1056/NEJMoa1607887
25. Talmor-Barkan Y, Yacovzada NS, Rossman H, Witberg G, Kalka I, Kornowski R, et al. Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial. Eur Heart J Cardiovasc Pharmacother. 2022;9(1):26–37. doi: https://doi.org/10.1093/ehjcvp/pvac063
26. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16. doi: https://doi.org/10.1007/s40262-013-0100-7
27. Sörensen I, Susnik N, Inhester T, Degen JL, Melk A, Haller H, et al. Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int. 2011;80(10):1035–44. doi: https://doi.org/10.1038/ki.2011.214
28. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008;14(10):429–40. doi: https://doi.org/10.1016/j.molmed.2008.08.001
29. Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res. 2016;118(9):1392–408. doi: https://doi.org/10.1161/CIRCRESAHA.116.306853
30. Brinkman HJM, Mertens K, Holthuis J, Zwart-Huinink LA, Grijm K, Van Mourik JA. The activation of human blood coagulation factor X on the surface of endothelial cells: a comparison with various vascular cells, platelets and monocytes. Br J Haematol. 1994;87(2):332–42. doi: https://doi.org/10.1111/j.1365-2141.1994.tb04918.x
31. Kim CS, Mathew AP, Vasukutty A, Uthaman S, Joo SY, Bae EH, et al. Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis. J Nanobiotechnol. 2021;19(1):109. doi: https://doi.org/10.1186/s12951-021-00857-w
32. Kim CS, Kim IJ, Choi JS, Bae EH, Ma SK, Kim SW. Tamoxifen ameliorates obstructive nephropathy through Src and the PI3K/Akt/mTOR pathway. Biol Cell. 2019;111(1):18–27. doi: https://doi.org/10.1111/boc.201800040
33. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: The master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325–38. doi: https://doi.org/10.1038/nrneph.2016.48
34. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684–96. doi: https://doi.org/10.1038/nrneph.2011.149
35. Goto M, Miura S ichiro, Suematsu Y, Idemoto Y, Takata K, Imaizumi S, et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice. Int J Cardiol. 2016:220:602–7. doi: https://doi.org/10.1016/j.ijcard.2016.06.212
Year
Month
Therapeutic drug monitoring of tacrolimus in kidney transplant patients: Insights from an Indian tertiary care clinical setting
Chaitra Rao Karkal, Daksha Dineshchandra Shetty, Sara Hajizadeh Amzajerdi, Tejashree Pasumarthi, Shankar Prasad Nagaraju, Ravindra Attur Prabhu, Surulivelrajan MallayasamyEvaluation of D-dimer level among adult patients in Al-Quwayyah Government Hospital, Saudi Arabia
The glucose uptake of type 2 diabetic rats by Sargassum olygocystum extract: In silico and in vivo studies
Muhamad Firdaus, Rahmi Nurdiani , Bachtiar Rivai, Windy Hapsari Hemassonida, Aqilatul Badzliyah, Nur Khasanah Sugiat